Recent discoveries in genetics and genomics hold great promise for the development of target-defined prevention and chemotherapeutic strategies for gynecological cancers, including biomarkers development for targeted therapy and immunotherapy.
However, a coordinated, multi-disciplinary research effort is required to translate these new research discoveries into the next generation of therapeutic strategies.
To meet this challenge the Gynecologic Cancer Research Program aims to:
Since its inception, the program has successfully fostered scientific interactions between members of the Duke Cancer Institute who have basic, translational, and clinical research interests in gynecologic cancer.
Within the domain of the program we developed five subprograms that draw from our translational research strength and ability to translate basic science discoveries to impact the early detection and treatment of gynecologic cancer:
The diversity of interest and experimental approaches used by the members of the Gynecologic Cancer Research Program represents an effective environment for fostering cross-fertilization of ideas aimed at understanding gynecologic cancer. In addition, the Program supports developmental projects, new faculty awards, and tissue procurement and banking.
Nationwide Ovarian Cancer Clinical Trial Shows Promise
Laura Elzie, 60, an IT architect with IBM, was first diagnosed with ovarian cancer three years ago. She turned to DCI gynecologic oncologist Angeles Secord, MD. Elzie underwent surgery followed by chemo-therapy. She later had the opportunity to participate in a clinical trial to potentially prolong remission. More
Duke Cancer Institute constellates the world-class resources of Duke University, Duke Health and the Duke Comprehensive Cancer Center into a collaborative powerhouse. We are poised to drive a paradigm shift in the way long-established cancer centers and institutes have been waging this war.Learn More